ReviewActa pharmaceutica Sinica. B2024
Design consideration of phthalocyanines as sensitizers for enhanced sono-photodynamic combinatorial therapy of cancer.
Review in Acta pharmaceutica Sinica. B, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 34 citations in OpenAlex.
- Beyond chemotherapy: the evolving role of photodynamic therapy in triple-negative breast cancer.Medical oncology (Northwood, London, England) · 2026Review
- Synthesis and Characterization of Novel Non-Peripheral Phthalocyanines for Efficient Singlet Oxygen Generation: Comparison of Photochemical and Sonophotochemical Methods.Journal of fluorescence · 2026Article
- Research progress on two-dimensional phthalocyanine materials: from molecular design to exploration of multifunctional applications.RSC advances · 2026Review
- Light and ultrasound activated precision: a novel water-soluble BODIPY-mediated sono-photosensitizer in SPDT for breast cancer treatment.Scientific reports · 2026Article
- Immunosuppressive Microenvironment Reprogramming by Synergistic Sonodynamic Therapy of Phthalocyanine-MOF Hybrids for Hepatocellular Carcinoma.Exploration (Beijing, China) · 2026Article
- Water-soluble ZnPc(COOH)RSC advances · 2025Article
- Applications and enhancement strategies of ROS-based non-invasive therapies in cancer treatment.Redox biology · 2025Review
- Nanocatalytic medicine enabled next-generation therapeutics for bacterial infections.Materials today. Bio · 2024Review
- RNA-Seq Reveals the Mechanism of Pyroptosis Induced by Oxygen-Enriched IR780 Nanobubbles-Mediated Sono-Photodynamic Therapy.International journal of nanomedicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains one of the diseases with the highest incidence and mortality globally. Conventional treatment modalities have demonstrated threatening drawbacks including invasiveness, non-controllability, and development of resistance for some, including chemotherapy, radiation, and surgery. Sono-photodynamic combinatorial therapy (SPDT) has been developed as an alternative treatment modality which offers a non-invasive and controllable therapeutic approach. SPDT combines the mechanism of action of sonodynamic therapy (SDT), which uses ultrasound, and photodynamic therapy (PDT), which uses light, to activate a sensitizer and initiate cancer eradication. The use of phthalocyanines (Pcs) as sensitizers for SPDT is gaining interest owing to their ability to induce intracellular oxidative stress and initiate toxicity under SDT and PDT. This review discusses some of the structural prerequisites of Pcs which may influence their overall SPDT activities in cancer therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.